JP7440134B2 - 特異的機能性物質の探索方法、特異的機能性物質探索装置、特異的機能性物質探索方法、及び、プログラム - Google Patents
特異的機能性物質の探索方法、特異的機能性物質探索装置、特異的機能性物質探索方法、及び、プログラム Download PDFInfo
- Publication number
- JP7440134B2 JP7440134B2 JP2022566992A JP2022566992A JP7440134B2 JP 7440134 B2 JP7440134 B2 JP 7440134B2 JP 2022566992 A JP2022566992 A JP 2022566992A JP 2022566992 A JP2022566992 A JP 2022566992A JP 7440134 B2 JP7440134 B2 JP 7440134B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- functional substance
- searching
- specific functional
- candidate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000126 substance Substances 0.000 title claims description 193
- 238000000034 method Methods 0.000 title claims description 108
- 108090000623 proteins and genes Proteins 0.000 claims description 166
- 102000004169 proteins and genes Human genes 0.000 claims description 165
- 238000010438 heat treatment Methods 0.000 claims description 78
- 230000000694 effects Effects 0.000 claims description 67
- 239000003112 inhibitor Substances 0.000 claims description 62
- 102000004190 Enzymes Human genes 0.000 claims description 58
- 108090000790 Enzymes Proteins 0.000 claims description 58
- 238000001816 cooling Methods 0.000 claims description 50
- 238000004088 simulation Methods 0.000 claims description 32
- 230000000865 phosphorylative effect Effects 0.000 claims description 30
- 230000000368 destabilizing effect Effects 0.000 claims description 26
- 230000001687 destabilization Effects 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 239000012190 activator Substances 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 10
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 9
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 239000000701 coagulant Substances 0.000 claims description 8
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- 239000003752 hydrotrope Substances 0.000 claims description 7
- 238000011105 stabilization Methods 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 108010047357 Luminescent Proteins Proteins 0.000 claims description 4
- 102000006830 Luminescent Proteins Human genes 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- -1 promoter Substances 0.000 claims description 4
- 230000006641 stabilisation Effects 0.000 claims description 4
- 108091008104 nucleic acid aptamers Proteins 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 108010078791 Carrier Proteins Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 claims description 2
- 108090000862 Ion Channels Proteins 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 102000005431 Molecular Chaperones Human genes 0.000 claims description 2
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims description 2
- 101710172711 Structural protein Proteins 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 210000004492 nuclear pore Anatomy 0.000 claims description 2
- 108020004017 nuclear receptors Proteins 0.000 claims description 2
- 108090000565 Capsid Proteins Proteins 0.000 claims 1
- 102000007999 Nuclear Proteins Human genes 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 description 77
- 238000010586 diagram Methods 0.000 description 70
- 150000001875 compounds Chemical class 0.000 description 66
- 229940088598 enzyme Drugs 0.000 description 53
- 239000000543 intermediate Substances 0.000 description 43
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 33
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 33
- 230000006870 function Effects 0.000 description 29
- 230000008569 process Effects 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 20
- 230000008859 change Effects 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 238000012216 screening Methods 0.000 description 16
- 230000001419 dependent effect Effects 0.000 description 15
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 14
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 14
- 238000004891 communication Methods 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 12
- 210000004748 cultured cell Anatomy 0.000 description 12
- 238000004364 calculation method Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 238000001262 western blot Methods 0.000 description 9
- 102000007590 Calpain Human genes 0.000 description 8
- 108010032088 Calpain Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000010365 information processing Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000000087 stabilizing effect Effects 0.000 description 7
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 6
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 6
- 102100033363 Dual specificity tyrosine-phosphorylation-regulated kinase 1B Human genes 0.000 description 6
- RERZNCLIYCABFS-UHFFFAOYSA-N Harmaline hydrochloride Natural products C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 6
- 101000926738 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1B Proteins 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- VJHLDRVYTQNASM-UHFFFAOYSA-N harmine Natural products CC1=CN=CC=2NC3=CC(=CC=C3C=21)OC VJHLDRVYTQNASM-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000329 molecular dynamics simulation Methods 0.000 description 5
- 230000020175 protein destabilization Effects 0.000 description 5
- KVCGISUBCHHTDD-UHFFFAOYSA-M sodium;4-methylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1 KVCGISUBCHHTDD-UHFFFAOYSA-M 0.000 description 5
- 238000000547 structure data Methods 0.000 description 5
- QGWNDRXFNXRZMB-UUOKFMHZSA-K GDP(3-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-K 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000007876 drug discovery Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000004853 protein function Effects 0.000 description 4
- 229940048842 sodium xylenesulfonate Drugs 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 238000000126 in silico method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000009454 functional inhibition Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- JBVOQKNLGSOPNZ-UHFFFAOYSA-N 2-propan-2-ylbenzenesulfonic acid Chemical compound CC(C)C1=CC=CC=C1S(O)(=O)=O JBVOQKNLGSOPNZ-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101000783817 Agaricus bisporus lectin Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102000038625 CMGCs Human genes 0.000 description 1
- 108091007913 CMGCs Proteins 0.000 description 1
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 241001001781 Citrus karna Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 1
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000944251 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Calcium/calmodulin-dependent protein kinase cmkA Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100287682 Homo sapiens CAMK2G gene Proteins 0.000 description 1
- 101100126883 Homo sapiens CAMK4 gene Proteins 0.000 description 1
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 101710171731 Mono-ADP-ribosyltransferase Proteins 0.000 description 1
- 241001508687 Mustela erminea Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940071118 cumenesulfonate Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
まず、本発明にかかる本実施形態の概要について説明する。図1は、本発明にかかる本実施形態の概要を概念的に示した図である。
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088748/、
https://www.sciencedirect.com/science/article/abs/pii/S0969212619303910?via%3Dihub、
隠れた結合部位(天然構造ではなく、非天然構造において出現する化合物が結合する部位)についての参考文献:
https://www.amed.go.jp/news/seika/kenkyu/20201005.html)。
次に、上述した本実施形態をシミュレーションにより実施する形態の一例である選択的機能性物質探索装置100の構成について図5を参照して説明する。なお、以下の記載事項を手動または自動による方法に適用してもよいものである。図5は、本実施形態が適用される本選択的機能性物質探索装置100の一例を示すブロック図であり、該構成のうち本実施形態に関係する部分を中心に概念的に示している。
以下、上述した図4以外にも、本発明にかかる実施形態の様々な実施例について説明を行う。ここで、図7Aは、2種類のフォールディング中間体特異的阻害剤における、加熱・急冷による完成型酵素活性の阻害効果を示す図である。また、図7Bは、2種類のフォールディング中間体特異的阻害剤における、加熱・急冷による完成型酵素活性の阻害効果に濃度依存性があることを示す図である。また、図7Cは、コントロールとして既知の物質RD0392および既知の物質Harmineを用いて阻害効果を測定した図である。また、図7Dは、培養細胞での実験結果を示す図である。なお、FINDYと化合物168(別名:CBT-168/dp-FINDY)は、以下の化学式で表され、上述のように本願発明者により2種類のフォールディング中間体特異的阻害剤としての効果をもつものとして確かめられている。なお、Harmineは、植物由来のアルカロイド化合物であり、リン酸化酵素DYRK1Aに対する阻害活性が多数の論文により報告されていることから、従来技術のポジティブコントロールとして使用した。
リン酸化酵素DYRK1Aタンパク質量 25 ng
DMSO濃度:0.3% in 25μL
ATP・基質ペプチド(DYRKtideペプチド:アミノ酸配列RRRFRPASPLRGPPK)濃度: 5μM each
酵素反応時のVol:25μL
サーマルサイクラー(Biometra TAdvancedモデル96SG)内Vol:15μL
酵素反応時間:2時間30分
加熱時間:20秒
加熱速度:8℃/秒
加熱温度:37℃~65℃
阻害剤:FINDY・化合物168 各30μM
1. 白色96-well PCRプレートのチューブ内でDYRK1Aタンパク質、阻害剤(阻害剤0μM時は溶媒DMSOのみを添加)、バッファー(終濃度:5 mM MOPS pH 7.2、2.5 mM beta-glycerol-phosphate、5 mM MgCl2、1 mM EGTA、0.4 mM EDTA、0.05 mM DTT)、超純水を混合した。[ボリューム:15μL DYRK1Aタンパク質量:25 ng 阻害剤濃度:30μM]
2. プレートをサーマルサイクラーにセットし、各加熱温度で20秒間加熱、その後3℃で10秒間冷却した。[加熱速度・冷却速度共に8℃/秒]
3. 冷却が終わったら、直ちに取り出し、ATP・基質ペプチド混合溶液を10μL加えた。[ボリューム:15μL→25μL ATP・基質ペプチド濃度 5μM]
4. サーマルサイクラーに再びセットし、20℃で2時間30分酵素反応させた。
5. サーマルサイクラーから取り出し、kinase Glo反応液を25μL加え、その発光値から残存ATP量を測定し酵素活性を評価した。[ボリューム:25μL→50μL]
つづいて、上述したリン酸化酵素以外のタンパク質として、モノアミン酸化酵素MAO-Aと、タンパク質分解酵素Calpain-Iについて、阻害剤および活性化剤の探索と検討を行った。
温度ジャンプの分子動力学(MD)シミュレーションの実施例について以下に説明する。
さて、これまで本発明の実施の形態について説明したが、本発明は、上述した実施の形態以外にも、特許請求の範囲に記載した技術的思想の範囲内において種々の異なる実施の形態にて実施されてよいものである。
102 制御部
102a 不安定化部
102b 判定部
102c 機器制御部
104 通信制御インターフェイス部
106 記憶部
106a 構造ファイル
106b 評価ファイル
108 入出力制御インターフェイス
112 入力部
114 出力部
200 外部機器
300 ネットワーク
Claims (11)
- タンパク質の非天然構造に特異的に結合し、前記タンパク質の機能に影響を与える機能性物質を探索する特異的機能性物質の探索方法であって、
前記タンパク質を、少なくとも部分的に、加熱により不安定化させるステップと、
機能性物質候補の存在下で、前記不安定化された前記タンパク質を供し、冷却により再安定化を促すステップと、
前記機能性物質候補の存在による、前記タンパク質が有する機能に対して影響を与える効果を判定するステップと、
を含む特異的機能性物質の探索方法。 - 請求項1に記載の特異的機能性物質の探索方法において、
前記タンパク質は、
酵素、発光タンパク質、その他の機能性タンパク質であり、
前記その他の機能性タンパク質は、Gタンパク質共役型受容体、イオンチャンネル、構造タンパク質、核膜孔複合体構成タンパク質、細胞膜受容体タンパク質、サイトカイン、分子シャペロン、トランスポーター、インテグリン、核内受容体、またはウイルス外殻タンパク質である、
特異的機能性物質の探索方法。 - 請求項2に記載の特異的機能性物質の探索方法において、
前記酵素は、リン酸化酵素、タンパク質分解酵素、またはモノアミン酸化酵素MAO-Aである、特異的機能性物質の探索方法。 - 請求項1~3のいずれかに記載の特異的機能性物質の探索方法において、
前記タンパク質を不安定化させる温度は、50℃~70℃である
特異的機能性物質の探索方法。 - 請求項1~4のいずれかに記載の特異的機能性物質の探索方法において、
前記タンパク質の機能は、基質ないし結合物質の存在下で発揮されるものである
特異的機能性物質の探索方法。 - 請求項1~5のいずれかに記載の特異的機能性物質の探索方法において、
界面活性剤またはハイドロトロープの存在下で、前記不安定化された前記タンパク質に対する前記機能性物質候補の活性を、機能性物質候補が存在しない場合のタンパク質の機能に対して、機能性物質候補が存在する場合のタンパク質の機能が1.5倍以上高まるか又は低下するような条件下で、検出するものである
特異的機能性物質の探索方法。 - 請求項1~6のいずれかに記載の特異的機能性物質の探索方法において、
前記機能性物質候補は、
低分子、中分子、高分子、ペプチド、抗体、または、核酸アプタマーである
特異的機能性物質の探索方法。 - 請求項1~7のいずれかに記載の特異的機能性物質の探索方法において、
前記機能性物質は、
前記タンパク質の阻害剤、促進剤、凝固剤、安定化剤、または、活性化剤である
特異的機能性物質の探索方法。 - タンパク質の非天然構造に特異的に結合し、前記タンパク質の機能に影響を与える機能性物質を探索する、少なくとも記憶部と制御部を備えた特異的機能性物質探索装置であって、
前記記憶部は、少なくとも1つの機能性物質候補に関する構造データを記憶しており、
前記制御部は、
シミュレーションにより、前記タンパク質を、少なくとも部分的に、加熱により不安定化させ、前記機能性物質候補の存在下で、前記不安定化された前記タンパク質を供し、さらに冷却により再安定化を促す不安定化/再安定化部と、
前記機能性物質候補の存在による、前記タンパク質が有する機能に対して影響を与える効果を判定する判定部と、
を備えたことを特徴とする特異的機能性物質探索装置。 - タンパク質の非天然構造に特異的に結合し、前記タンパク質の機能に影響を与える機能性物質を探索するため、少なくとも記憶部と制御部を備えたコンピュータに実行させる特異的機能性物質探索方法であって、
前記記憶部は、少なくとも1つの機能性物質候補に関する構造データを記憶しており、
前記制御部において実行される、
シミュレーションにより、前記タンパク質を、少なくとも部分的に、加熱により不安定化させ、前記機能性物質候補の存在下で、前記不安定化された前記タンパク質を供し、さらに冷却により再安定化を促す不安定化/再安定化ステップと、
前記機能性物質候補の存在による、前記タンパク質が有する機能に対して影響を与える効果を判定する判定ステップと、
を含むことを特徴とする特異的機能性物質探索方法。 - タンパク質の非天然構造に特異的に結合し、前記タンパク質の機能に影響を与える機能性物質を探索するため、少なくとも記憶部と制御部を備えたコンピュータに実行させるためのプログラムであって、
前記記憶部は、少なくとも1つの機能性物質候補に関する構造データを記憶しており、
前記制御部において実行される、
シミュレーションにより、前記タンパク質を、少なくとも部分的に、加熱により不安定化させ、前記機能性物質候補の存在下で、前記不安定化された前記タンパク質を供し、さらに冷却により再安定化を促す不安定化/再安定化ステップと、
前記機能性物質候補の存在による、前記タンパク質が有する機能に対して影響を与える効果を判定する判定ステップと、
を実行させるためのプログラム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020201892 | 2020-12-04 | ||
JP2020201892 | 2020-12-04 | ||
PCT/JP2021/044375 WO2022118941A1 (ja) | 2020-12-04 | 2021-12-02 | 選択的機能性物質の探索方法、選択的機能性物質探索装置、選択的機能性物質探索方法、および、プログラム |
Publications (3)
Publication Number | Publication Date |
---|---|
JPWO2022118941A1 JPWO2022118941A1 (ja) | 2022-06-09 |
JPWO2022118941A5 JPWO2022118941A5 (ja) | 2023-09-15 |
JP7440134B2 true JP7440134B2 (ja) | 2024-02-28 |
Family
ID=81853390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022566992A Active JP7440134B2 (ja) | 2020-12-04 | 2021-12-02 | 特異的機能性物質の探索方法、特異的機能性物質探索装置、特異的機能性物質探索方法、及び、プログラム |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240013855A1 (ja) |
EP (1) | EP4257700A1 (ja) |
JP (1) | JP7440134B2 (ja) |
WO (1) | WO2022118941A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180064672A1 (en) | 2015-01-09 | 2018-03-08 | Mcmaster University | Allosteric activators for treatment of phenylketonuria |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013183718A1 (ja) * | 2012-06-06 | 2013-12-12 | 国立大学法人京都大学 | スクリーニング方法、タンパク質の不安定性及び/又は安定性を誘導する物質、及び、タンパク質の活性評価 |
-
2021
- 2021-12-02 JP JP2022566992A patent/JP7440134B2/ja active Active
- 2021-12-02 WO PCT/JP2021/044375 patent/WO2022118941A1/ja active Application Filing
- 2021-12-02 US US18/255,831 patent/US20240013855A1/en active Pending
- 2021-12-02 EP EP21899305.3A patent/EP4257700A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180064672A1 (en) | 2015-01-09 | 2018-03-08 | Mcmaster University | Allosteric activators for treatment of phenylketonuria |
Non-Patent Citations (4)
Title |
---|
MIYAZAKI, Y. et al.,Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A,Eur. J. Med. Chem.,2021年10月28日,Vol. 227:113948,pp. 1-18 |
NORDHOFF, A. et al.,Denaturation and reactivation of dimeric human glutathione reductase. An assay for folding inhibitors,Eur. J. Biochem.,1997年,Vol. 245,pp. 273-282 |
UMEZAWA, K. et al.,Druggable Transient Pockets in Protein Kinases,Molecules,2021年01月27日,Vol. 26:651,pp. 1-16 |
平野 篤 ほか,姿をかえるタンパク質,生物工学,2011年,Vol. 89,pp. 404-407 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022118941A1 (ja) | 2022-06-09 |
EP4257700A1 (en) | 2023-10-11 |
WO2022118941A1 (ja) | 2022-06-09 |
US20240013855A1 (en) | 2024-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs | |
Shannon et al. | Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis | |
Ames et al. | Bacterial aptamers that selectively bind glutamine | |
Browne et al. | A chemoproteomic strategy for direct and proteome-wide covalent inhibitor target-site identification | |
Thinon et al. | Global profiling of co-and post-translationally N-myristoylated proteomes in human cells | |
Fedorov et al. | Kinase inhibitor selectivity profiling using differential scanning fluorimetry | |
Krishna et al. | A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4 | |
Nainar et al. | Metabolic incorporation of azide functionality into cellular RNA | |
Zhang et al. | Quantitative proteomics analysis reveals BAG3 as a potential target to suppress severe acute respiratory syndrome coronavirus replication | |
Suganuma et al. | STIM1 regulates platelet-derived growth factor-induced migration and Ca2+ influx in human airway smooth muscle cells | |
Ruprecht et al. | A mass spectrometry-based proteome map of drug action in lung cancer cell lines | |
Scutt et al. | Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks | |
Graidist et al. | Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil-induced cytotoxicity | |
Watson et al. | Kinase inhibition profiles as a tool to identify kinases for specific phosphorylation sites | |
Ueda et al. | Proteomic identification of Bcl2-associated athanogene 2 as a novel MAPK-activated protein kinase 2 substrate | |
Giansanti et al. | Dynamic remodelling of the human host cell proteome and phosphoproteome upon enterovirus infection | |
Tee et al. | Staurosporine inhibits phosphorylation of translational regulators linked to mTOR | |
Maurer et al. | Discovery of the first small-molecule CsrA–RNA interaction inhibitors using biophysical screening technologies | |
Mayer et al. | An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro | |
Samson et al. | p90 ribosomal S6 kinase (RSK) phosphorylates myosin phosphatase and thereby controls edge dynamics during cell migration | |
Knight et al. | Profiling the kinome: current capabilities and future challenges | |
William et al. | Medaka osmotic stress transcription factor 1b (Ostf1b/TSC22D3-2) triggers hyperosmotic responses of different ion transporters in medaka gill and human embryonic kidney cells via the JNK signalling pathway | |
Qiu et al. | Exploring DNA-binding proteins with in vivo chemical cross-linking and mass spectrometry | |
Friman et al. | CETSA MS profiling for a comparative assessment of FDA-approved antivirals repurposed for COVID-19 therapy identifies TRIP13 as a remdesivir off-target | |
Narushima et al. | Integrative network analysis combined with quantitative phosphoproteomics reveals transforming growth factor-beta receptor type-2 (TGFBR2) as a novel regulator of glioblastoma stem cell properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230412 |
|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A5211 Effective date: 20230412 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20230412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230412 |
|
AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20230620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230719 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230810 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230412 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231115 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240207 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7440134 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |